Pharmacyclics Switzerland GmbH
2 clinical trials · Sponsor
◉ Watch Pharmacyclics Switzerland GmbH
| Record | Firm | Date |
|---|---|---|
| Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. (NCT03229200) | Pharmacyclics Switzerland GmbH | 2017-05-22 |
| Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma (NCT02902965) | Pharmacyclics Switzerland GmbH | 2016-09-20 |
Track Pharmacyclics Switzerland GmbH automatically
Every clearance here is in the API, with alerts when new ones post.